Abstract 189P
Background
This study evaluates the local control rates of patients treated with Stereotactic Body Radiotherapy (SBRT) for unresectable primary Hepatocellular carcinoma and oligometastatic liver lesions.
Methods
21 patients with 26 lesions treated with SBRT between February 2015 and March 2018. 3/21(14.2%) patients were primary hepatocellular carcinoma, 2/21(9.4%) were primary cholangiocarcinoma and 16/21(76.1%) patients were metastatic lesions. 16/21 patients had single, 3/21patients had two and 1/21 patient had three lesions. Patients were immobilized with thermoplastic mask with an indigenous abdominal compression device for motion management. Radiation planning triple phase CT scan with slice thickness of 1mm were fused with PET/CT scan and MRI scan. GTV is delineated and ITV is generated based on CT image data set in multiple phases of respiration. Adequate PTV margin was given.2/21(9.4%) patients were treated with IMRT technique, 17/21(79%) were planned with volumetric arc technique and 2/21(9.4%) were treated with helical Tomotherapy. The mean volume of the lesions treated was 31.1cc (Range,1.5cc to 314.9cc). Dose ranged from 18Gy-24Gy in single fraction, 24Gy-54Gy in three fractions and 30Gy-50Gy in 5 fractions. Mean volume of normal liver is 1195cc. Mean dose to 700cc of normal liver was 365.8cGy (Range, 11.7cGy-1428.6cGy). All the patients received different types of systemic therapy also.
Results
The median follow up was 24 months.All 21 patients were evaluable for response based on triple phase computed tomography scan obtained in every 3 months after completion of SBRT. All 5/5(100%) patients of primary HCC and cholangiocarcinoma and 15/16 (93.7%) patients with metastatic lesionswere in radiological complete response at local site at the end of 12 months. Two year local control rate for metastatic lesions was 90%. there was no grade 3 or higher toxicity.
Conclusions
In our series of 21 patients of primary hepatocellular carcinoma and oligometastatic liver lesions excellent local control has been achieved by SBRT with acceptable toxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract